SPRAVATO is a novel medication for individuals suffering from Treatment Resistant Depression (TRD). This treatment is a form of ketamine that is administered intranasally to improve mood. SPRAVATO was approved by the FDA in March 2019, making it one of the first treatments approved in decades.
Nearly 50% of patients with depression do not respond to their first treatment with oral antidepressants, and up to one-third of patients will not see improvements after four courses of treatment. This may result in a diagnosis of TRD. However, TRD does not have to be a hopeless diagnosis. Use of SPRAVATO in conjunction with an oral antidepressant has been shown to result in a rapid abatement of depression symptoms in those who have not responded to antidepressants. Furthermore, preliminary long term results favor the use of SPRAVATO in preventing depression relapse. Talk to Dr. Gupta to see if SPRAVATO may help you feel better.
